Cel Sci (CVM) Interest & Investment Income (2010 - 2015)
Cel Sci (CVM) posted Interest & Investment Income of -$49682.0 for Q3 2015, down 287.98% sequentially from $26429.0 in Q2 2015, and up 33.03% YoY from -$37347.3 in Q3 2014.
Cel Sci (CVM) Interest & Investment Income (2010 - 2015) Analysis & Trends
Cel Sci has reported Interest & Investment Income for 6 years, with the latest figure at -$49682.0 in Q3 2015.
- Quarterly Interest & Investment Income rose 33.03% year-over-year to -$49682.0 in Q3 2015, while the trailing twelve-month figure through Sep 2015 was $33390.0 (up 73.44% YoY) and the FY2019 annual result came in at -$1.8 million, up 57.36% from the prior year.
- Interest & Investment Income slipped to -$49682.0 in Q3 2015 per CVM's latest filing, from $26429.0 in the prior quarter.
- Over five years, Interest & Investment Income peaked at $46707.0 in Q1 2011 and troughed at -$74182.0 in Q3 2014.
- A 5-year average of $12859.1 and a median of $29027.0 in 2013 frame the typical range for Interest & Investment Income.
- The widest YoY moves for Interest & Investment Income: up 25305.6% in 2013, down 689.16% in 2013.
- Over 5 years, Interest & Investment Income stood at $29055.0 in 2011, then tumbled by 99.57% to $125.0 in 2012, then surged by 25305.6% to $31757.0 in 2013, then retreated by 8.33% to $29112.0 in 2014, then slumped by 270.66% to -$49682.0 in 2015.
- According to Business Quant data, Interest & Investment Income over the past three periods registered -$49682.0, $26429.0, and $27531.0 for Q3 2015, Q2 2015, and Q1 2015 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | Cel Sci | 2.12 Mn | -4.42 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2015 | -49,682.00 |
| Jun 30, 2015 | 26,429.00 |
| Mar 31, 2015 | 27,531.00 |
| Dec 31, 2014 | 29,112.00 |
| Sep 30, 2014 | -74,182.00 |
| Jun 30, 2014 | 30,795.00 |
| Mar 31, 2014 | 30,882.00 |
| Dec 31, 2013 | 31,757.00 |
| Sep 30, 2013 | -58,666.00 |
| Jun 30, 2013 | 29,027.00 |
| Mar 31, 2013 | 30,952.00 |
| Dec 31, 2012 | 125.00 |
| Sep 30, 2012 | -7,434.00 |
| Jun 30, 2012 | 28,665.00 |
| Mar 31, 2012 | 28,673.00 |
| Dec 31, 2011 | 29,055.00 |
| Sep 30, 2011 | 30,161.00 |
| Jun 30, 2011 | 34,416.00 |
| Mar 31, 2011 | 46,707.00 |
| Dec 31, 2010 | 52,879.00 |